This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Events & Webinars
  • Podcasts
  • Resources
  • Learning Zone
  • Products
  • Service Optimisation & Formularies
  • Risk Minimisation Materials
Cardiovascular
Cardiovascular
Womens Health
Women's Health
two kidneys
Nephrology
Oncology
Oncology
Ophthalmology
Ophthalmology
Respiratory
Respiratory
Bayer cross colorful
Bayer for ProfessionalsYour Resource Portal
closesearch
Recent Searches
    You are now leaving BayerPro

    The contents and the policies on the website you are visiting is not controlled by the BayerPRO team.
    Do you wish to continue?

    Products
    NUBEQA® (darolutamide)
    In nmCRPC and mHSPC
    NUBEQA Prescribing Information
    PP-NUB-GB-2217, March 2025
    Xofigo®▼ (radium-223 dichloride)
    In mCRPC
    Xofigo Prescribing Information
    PP-XOF-GB-0648, April 2025
    Resources
    View more
    NUBEQA® (darolutamide) Resources
    NUBEQA Prescribing Information
    PP-NUB-GB-2048, February 2025
    Xofigo®▼ (radium-223 dichloride) Resources
    Xofigo Prescribing Information
    PP-XOF-GB-0626, April 2025
    Gathering consensus on mHSPC Treatment
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2230, March 2025
    nmCRPC Patient Case Study
    NUBEQA® (darolutamide) - A Urologist Perspective
    NUBEQA Prescribing Information
    PP-NUB-GB-2038, January 2025
    Events & Webinars
    View more
    ASCO-GU 2023: The DEAR study in nmCRPC
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2022, January 2025
    BAUS 2024: Imaging and nmCRPC
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2081, January 2025
    BAUS 2024: Management of CV toxicity and bone health
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2079, January 2025
    BAUS 2024: Urology and Oncology in Partnership
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2080, January 2025
    Podcasts
    View more
    ASCO GU 2025
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2229, March 2025
    Learning Zone
    View more
    Request An Interactive Pharmacist’s Guide
    NUBEQA® (darolutamide)
    NUBEQA Prescribing Information
    PP-NUB-GB-2388, May 2025
    NUBEQA® (darolutamide) Drug-Drug Interactions Learning Guide
    NUBEQA Prescribing Information
    PP-NUB-GB-2129, March 2025
    Module 4: MI Course
    Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
    Xofigo Prescribing Information
    NUBEQA Prescribing Information
    RP-NUB-GB-0713, January 2025
    Module 3: MI Course
    Xofigo®▼ (radium-223 dichloride) | NUBEQA® (darolutamide)
    Xofigo Prescribing Information
    NUBEQA Prescribing Information
    RP-NUB-GB-0712, January 2025

    Register with BayerPRO

    To access additional resources, personalise your experience and keep up to date via electronic communications from Bayer.

     

    Areas of Interest
    Cardiovascular
    Women's Health
    Nephrology
    Oncology
    Ophthalmology
    Respiratory